• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc. (Amendment)

    5/31/24 10:36:52 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTC alert in real time by email
    SC 13G/A 1 tm2416145d1_sc13ga.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C.  20549

     

     

     

    SCHEDULE 13G

    (Amendment no. 2)

     

    (Rule 13d-102)

     

    Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments

    Thereto Filed Pursuant to § 240.13d-2.

     

    Under the Securities Exchange Act of 1934

     

    China SXT Pharmaceuticals Inc

    (Name of Issuer)

     

              COMMON STOCK, PAR VALUE $0.08PER SHARE          

    (Title of Class of Securities)

     

              G2161P140          

    (CUSIP Number)

     

                        May 30, 2024                    

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)
    ¨Rule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

     

    Page 1 of 6 Pages

     

     

     

     

    CUSIP No.: G2161P140SCHEDULE 13GPage 2 of 6 Pages

     

    1)

    NAME OF REPORTING PERSON

     

    Forsakringsaktiebolaget Avanza Pension

    2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

    3)

    SEC USE ONLY

     

     

    4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Stockholm, Sweden

      NUMBER
    OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5)

    SOLE VOTING POWER

     

    30,679

    6)

    SHARED VOTING POWER

     

     

    7)

    SOLE DISPOSITIVE POWER

     

     

    8)

    SHARED DISPOSITIVE POWER

     

    30,679

    9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    30,679

    10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

    11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5,42 %

    12)

    TYPE OF REPORTING PERSON

     

    FI

             

     

    CUSIP No.: G2161P140SCHEDULE 13GPage 3 of 6 Pages

     

    Item 1(a).Name of Issuer:

     

    China SXT Pharmaceuticals Inc

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    178 Taidong Road North

    TAIZHOU, JNG, 225300

    China

     

    Item 2(a).Name of Person Filing:

     

    Forsakringsaktiebolaget Avanza Pension

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    Box 1399

    STOCKHOLM, 11139

    SWEDEN

     

    Item 2(c).Citizenship:

     

    Forsakringsaktiebolaget Avanza Pension is a company organized under the laws of Sweden

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, Par Value $0.08 per share

     

    Item 2(e).CUSIP Number:  G2161P140

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)

     

      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)

     

      (c) ¨ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)

     

      (d) ¨ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)

     

      (e) ¨ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)

     

      (f) ¨ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)

     

      (g) ¨ Parent Holding Company or control person in accordance with §240.13d-1(b)(1)(ii)(G)

     

      (h) ¨ Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)

     

      (i) ¨ Church plan that is excluded from the definition of an investment company under §3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)

     

      (j) x A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)

     

      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K)

     

     

    CUSIP No.: G2161P140SCHEDULE 13GPage 4 of 6 Pages

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:  30,679

     

    (b)Percent of class: 5,42 %

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:  30,679

     

    (ii)Shared power to vote or to direct the vote:  None

     

    (iii)Sole power to dispose or to direct the disposition of:  None

     

    (iv)Shared power to dispose or to direct the disposition of: 30,679

     

    Number and Percentage
    of Shares Beneficially Owned
      Date
    5,42 % / 30,679  May 30, 2024

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not applicable

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

    CUSIP No.: G2161P140SCHEDULE 13GPage 5 of 6 Pages

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable

     

     

    CUSIP No.: G2161P140SCHEDULE 13GPage 6 of 6 Pages

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a Swedish insurance company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

    SIGNATURE

     

    After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

    May 31, 2024  
       
       
       
       
       
    Joakim Lomell / Middle Office  
    Name/Title  

     

     

    Get the next $SXTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SXTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

      TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that the Company received a written notification (the "Compliance Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Ru

      3/17/25 8:30:00 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China SXT Pharmaceuticals, Inc. Announces Share Consolidation

      TAIZHOU, China, Feb. 21, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the "Share Consolidation"). The Company's ordinary shares are expected to begin trading on a post-consolidation basis at the open of th

      2/21/25 12:35:28 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

      Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC) announced today that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. Under the Nasdaq List

      10/7/24 4:15:00 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      10/25/24 12:19:29 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      8/15/24 9:45:36 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc. (Amendment)

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      5/31/24 10:36:52 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    SEC Filings

    See more
    • SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

      424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/19/25 8:00:24 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by China SXT Pharmaceuticals Inc.

      6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/13/25 11:30:25 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

      424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/7/25 7:58:31 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

      XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

      4/25/23 8:30:00 AM ET
      $BON
      $SXTC
      $WSG
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Services-Misc. Amusement & Recreation